Drug intelligence / Profile preview

cannabidiol + clobetasol

Development stage: Unknown
Modality: Small Molecules
Administration: Topical

Overview

This is a combination of cannabidiol (CBD), a phytocannabinoid derived from cannabis that acts on the endocannabinoid system, and clobetasol, a high-potency topical corticosteroid. Cannabidiol is FDA-approved for treating seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Clobetasol is used to treat various inflammatory skin conditions including psoriasis, eczema, and dermatoses. This specific combination is not established as a standard treatment regimen.

Targets

GR (Glucocorticoid receptor)CNR1 (Cannabinoid receptor 1)SCN9A (Sodium channel protein type 9 subunit alpha)

Beyond the preview

Go deeper on cannabidiol + clobetasol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabidiol + clobetasol.

Explore the full profile